Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death

Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia

Addex Completes 2014 with Strong Cash Position and Provides 2015 Strategic Update

Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder

Addex Amends mGlu2PAM Collaboration Agreement and Receives USD757,000

Addex and the Charcot-Marie-Tooth Association enter collaboration to advance ADX71441 in Charcot-Marie-Tooth 1A disorder

Addex Therapeutics Reports First Half 2014 Financial Results

Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction

Addex Shareholders Approve All Board Proposals at Annual General Meeting

Addex Therapeutics Publishes Annual General Meeting Agenda